The abundance of IgA+ B cells in CIS/MS patients was significantly increased compared to controls, and there was also a trend towards an increased proportion of IgG3+ B cells circulating in CIS/MS patients compared to controls (Figure 2B) no difference between CIS and MS patients was observed (Supplementary Figure 2). This evidence concerns the gene CD79A and in situ carcinoma.